Recent progress in targeted therapy for non-small cell lung cancer.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Non-small cell lung cancer (NSCLC) presents significant morbidity and mortality.
• Advances in targeted therapies have improved patient prognosis.
• Unknown carcinogenic drivers and acquired drug resistance limit current NSCLC treatments.

Purpose of the Study:

• To review mechanisms of targeted-drug resistance in NSCLC.
• To identify and discuss newly discovered NSCLC targets.
• To highlight the importance of genetic alterations for individualized NSCLC therapy.

Main Methods:

• Literature review of scientific publications.
• Analysis of mechanisms underlying targeted-drug resistance.
• Identification and compilation of emerging NSCLC targets.

Main Results:

• Drug resistance is a major obstacle in NSCLC targeted therapy.
• Several novel targets (e.g., KRAS G12C, NGRs, DDRs, STK11/LKB1) are identified.
• Understanding resistance mechanisms and new targets is crucial for treatment.

Conclusions:

• Individualized therapy for NSCLC requires identifying genetic alterations.
• Exploring novel targets and resistance mechanisms will advance NSCLC treatment strategies.
• Further research into these areas promises improved outcomes for NSCLC patients.